|
Thursday, 29 September 2011 00:02 |
|
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive phase II clinical results showing that its ToleroMune® hay fever vaccine substantially improved patients' allergy symptoms compared with those on placebo.
|
|
Read more...
|
|
Thursday, 29 September 2011 00:00 |
|
MicroDose Therapeutx, Inc. today announced that the first human subject has been dosed in a Phase 1 clinical trial of MDT-637, MicroDose’s inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).
|
|
Read more...
|
|
Wednesday, 28 September 2011 17:25 |
|
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of a Phase 1/2 clinical trial with HTI-501 (rHuCAT-L) in women with moderate to severe edematous fibrosclerotic panniculopathy (also known as cellulite).
|
|
Read more...
|
|
Wednesday, 28 September 2011 17:18 |
|
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the preliminary findings of the Company's randomized, placebo-controlled, Phase 3 clinical study of BEMA Buprenorphine for the treatment of moderate to severe chronic pain in a mixed opioid naive and opioid experienced population.
|
|
Read more...
|
|
Tuesday, 27 September 2011 00:04 |
|
YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.
|
|
Read more...
|
|
Tuesday, 27 September 2011 00:02 |
|
The first randomised trial to investigate the use of trastuzumab emtansine (T-DM1) an antibody-guided drug for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening.
|
|
Read more...
|
|
Monday, 26 September 2011 16:43 |
|
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it is tripling the number of patients in its Phase 1b/2 clinical trial who will be treated with its tumor-targeting doxorubicin conjugate INNO-206 at the dose planned for its Phase 2b trial for the treatment of advanced soft tissue sarcomas. Six patients have already been treated at that dose, out of a total of 13 enrolled in the trial, and the Company now plans to add an additional 12 patients.
|
|
Read more...
|
|
Monday, 26 September 2011 16:41 |
|
Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited.
|
|
Read more...
|
|
Saturday, 24 September 2011 00:44 |
|
Bayer HealthCare Pharmaceuticals announced that the investigational drug radium-223 chloride showed positive data in the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial.
|
|
Read more...
|
|
Saturday, 24 September 2011 00:41 |
|
Butrans® (Buprenorphine) Transdermal System CIII 20 mcg/hour provided significantly lower "average pain over the last 24 hours" scores compared to Butrans 5 mcg/hour when used in opioid-experienced patients with moderate-to-severe chronic low back pain, according to a pivotal Phase 3 clinical study published in the online, August issue of The Journal of Pain.
|
|
Read more...
|
|
|
Thursday, 29 September 2011 00:01 |
|
Oramed Pharmaceuticals Inc. (http://www.oramed.com), a developer of oral delivery systems, announced that EnteraBio Ltd. recently reported successful Phase 1 clinical trial results.
|
|
Read more...
|
|
Wednesday, 28 September 2011 17:26 |
|
YM BioSciences Inc. (NYSE Amex: YMI) (TSX: YM) today announced that it has enrolled the first patients in its multi-center Phase II trial of CYT387 administered twice-daily (BID) for the treatment of myelofibrosis.
|
|
Read more...
|
|
Wednesday, 28 September 2011 17:21 |
|
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin® in metastatic pancreatic cancer.
|
|
Read more...
|
|
Tuesday, 27 September 2011 00:07 |
|
InSite Vision Incorporated (OTCBB:INSV) today announced the selection of Quintiles as the contract research organization to manage the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.
|
|
Read more...
|
|
Tuesday, 27 September 2011 00:03 |
|
The Harvard Clinical Research Institute (HCRI) announced today that the enrollment phase of the DAPT Study has been successfully completed.
|
|
Read more...
|
|
Monday, 26 September 2011 16:45 |
|
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.
|
|
Read more...
|
|
Monday, 26 September 2011 16:42 |
|
Resverlogix Corp. ("Resverlogix") (TSX:RVX) announces today that study sites for the Phase 2b ASSURE clinical trial have now been activated.
|
|
Read more...
|
|
Saturday, 24 September 2011 00:47 |
|
Delcath Systems (NASDAQ: DCTH) announced today that James F. Pingpank, MD, FACS, Associate Professor of Surgery at the University of Pittsburgh School of Medicine, will present updated investigator results from the Phase 3 randomized trial of Delcath's chemosaturation system with melphalan in patients with hepatic metastases from ocular or cutaneous melanoma.
|
|
Read more...
|
|
Saturday, 24 September 2011 00:42 |
|
A Phase III study of Afinitor® (everolimus) tablets* in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
|
|
Read more...
|
|
Friday, 23 September 2011 01:52 |
|
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.
|
|
Read more...
|
|
